Skip to content
Screener

Ironwood Pharmaceuticals IRWD Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$113.0MMiss by $1.8M
EPS$0.31Miss by $0.01
Revenue estimate$114.8M
EPS estimate$0.32
“Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profits and cash flows. We are pleased to report a second consecutive quarter of strong performance for LINZESS, fueled by improved net price and mid-single digit prescription demand growth which supported our decision to raise our full-year 2026 financial guidance. We also repaid our $200 million convertible notes during the quarter using cash on hand and remain committed to further debt reduction and strengthening our balance sheet through year end.”
Tom McCourt

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$120.0M
EPS estimate$0.30

Financials

Q2 2026

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%
EPS (diluted)$0.31+121%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M—

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$689.05M+231%
Enterprise value$621.79M+89.1%
P/E5.3×—
P/S1.8×+1.1×

Profitability

See full
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp

Returns & leverage

See full
Current ratio6.1×+5.2×

Segments

By product

See full
Royalty$1.1M+22.2%
Collaborative Arrangement Development And Commercialization Agreements$500.0K+119%

FAQ

When did Ironwood Pharmaceuticals report Q2 2026 earnings?
Ironwood Pharmaceuticals (IRWD) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Ironwood Pharmaceuticals's Q2 2026 revenue and EPS?
Ironwood Pharmaceuticals reported revenue of $113.0M and eps of $0.31 for Q2 2026.
Did Ironwood Pharmaceuticals beat estimates in Q2 2026?
Revenue missed the consensus estimate of $114.8M by $1.8M. EPS missed the consensus estimate of $0.32 by $0.01.
How did Ironwood Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 32.6% from $85.2M a year earlier and eps grew 121.4% from $0.14.
Where can I find Ironwood Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-091625) and the 10-Q periodic report (0001104659-26-091987) directly on SEC EDGAR. The filing index links above go to sec.gov.